AkkusMHKamanODoganM. Alectinib continuation during COVID 19 ‘antiviral’ treatment: risk or benefit?J Oncol Pharm Pract2021; 27: 1251–1254.
2.
McGeeMCAugustAHuangW. BTK/ITK dual inhibitors: modulating immunopathology and lymphopenia for COVID-19 therapy. J Leukoc Biol2021; 109: 49–53.
3.
PurcaruOSArteneSABarcanE, et al.The interference between SARS-CoV-2 and tyrosine kinase receptor signaling in cancer. Int J Mol Sci2021; 22: 4830.
4.
YaylaciSDheirHŞenocakD, et al.The effects of favipiravir on hematological parameters of COVID-19 patients. Rev Assoc Med Bras (1992)2020; 66(Suppl 2): 65–70.
5.
JoobBWiwanitkitV. Blood viscosity of COVID-19 patient: a preliminary report. Am J Blood Res2021; 11: 93–95.
